RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Perennial Real Estate Holdings, a Singapore company, announced a $1.2 billion joint venture that will acquire and develop healthcare centers in China. It plans to concentrate on integrated mixed-use developments, centered around healthcare, that are connected to China high speed railway stations. Perennial is already building two such properties, one in Chengdu and the other in Xi’an. Its major partner in the JV will be Shun Tak Holdings, a Hong Kong conglomerate. Perennial contributed $225 million to the first close of the JV, which is $500 million.
Source: China Biotoday
